GovWire

Research: ACMD review of the evidence on the use and harms of Cumyl-PeGaClone

Advisory Council On The Misuse Of Drugs

June 8
10:08 2023

ACMD review of the evidence on the use and harms of Cumyl-PeGaClone

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Letter from ACMD to the Home Secretary: ACMD review of Cumyl-PeGaClone

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

In 2022 the Advisory Council on the Misuse of Drugs (ACMD) was commissioned to give advice on the appropriate classification and scheduling of the synthetic cannabinoid receptor agonist (SCRA) Cumyl-PeGaClone under the Misuse of Drugs Act 1971. Cumyl-PeGaClone was added to schedule II of the Convention on Psychotropic Substances of 1971 during the 64th Commission on Narcotic Drugs (CND) meeting in April 2021.

The ACMD has therefore written this report describing the use and harms of Cumyl-PeGaClone and other recently encountered SCRA and has provided recommendations on their classification and scheduling.

We are aware this publication may have accessibility issues. We are reviewing it so that we can fix these. Read more about our accessible documents policy.

Published 25 May 2023
Last updated 8 June 2023 +show all updates
  1. An accessible version of the letter has been added.

  2. First published.

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: